- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01482260
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
November 5, 2012 updated by: Michael Sand, Ruhr University of Bochum
Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi
Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM).
This study will be an exploratory analysis by miRNA expression profiling using microarrays.
Study Overview
Detailed Description
Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM).
With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited.
Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays.
Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).
Study Type
Observational
Enrollment (Actual)
21
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
NRW
-
Bochum, NRW, Germany, 44791
- Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with
- Primary Cutaneous Malignant Melanoma
- Cutaneous Malignant Melanoma Metastases
- Benign Melanocytic Naevi
Description
Inclusion Criteria:
- Primary Cutaneous Malignant Melanoma
- Cutaneous Malignant Melanoma Metastases
- Benign Melanocytic Naevi
Exclusion Criteria:
- Other Skin Cancer than Primary Cutaneous Malignant Melanoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Benign Melanocytic Nevi
|
Biopsy
|
|
Primary Cutaneous Malignant Melanoma
|
Biopsy
|
|
Cutaneous Malignant Melanoma Metastases
|
Biopsy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Falk G Bechara, PD Dr., Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
- Study Chair: Peter Altmeyer, Prof. Dr., Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
November 26, 2011
First Submitted That Met QC Criteria
November 29, 2011
First Posted (Estimate)
November 30, 2011
Study Record Updates
Last Update Posted (Estimate)
November 6, 2012
Last Update Submitted That Met QC Criteria
November 5, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- microRNA5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Malignant Melanoma
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsCompletedHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompletedCutaneous Malignant MelanomaBelgium, Hungary
-
National Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Array BioPharmaTerminatedMetastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Locally Advanced Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC V8 | Clinical Stage IV Cutaneous Melanoma AJCC V8 | Pathologic Stage III Cutaneous Melanoma AJCC V8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC V8 and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
National Cancer Institute (NCI)CompletedUnresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Catalysis SLCompletedCutaneous Melanoma, Stage II | Cutaneous Melanoma, Stage III | Malignant Cutaneous MelanomaCuba
Clinical Trials on Biopsy
-
UNICANCERNational Cancer Institute, FranceActive, not recruitingTriple-Negative Breast NeoplasmFrance
-
Postgraduate Institute of Medical Education and...CompletedLung Cancer | Endobronchial GrowthIndia
-
Centre Hospitalier Universitaire de NiceCompletedParodontitis Aggressive | Parodontitis ChronicFrance
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
Duke UniversityCompletedInterstitial Lung DiseaseUnited States
-
Ardeshir RastinehadPhilips HealthcareRecruitingProstate Cancer | Prostate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Sanjay Gandhi Postgraduate Institute of Medical...RecruitingSarcoidosis Lung | Pulmonary SarcoidosisIndia
-
Mayo ClinicErbe USA IncorporatedCompletedLung Diseases, Obstructive | Bronchi--Diseases | Lesions MassUnited States
-
Hordinsky, Maria K., MDTerminated
-
Mayo ClinicRecruitingLung Transplant RejectionUnited States